United States · Platforms & data · Finviz

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Published by Finviz · United States 11 h ago

Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO ® upon close and infliximab-abda in Q3 2027; Collaboration combines Samsung Bioepis’ biosim ...

Read the full article on Finviz Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finviz.com)

Also worth reading

The Motley Fool

Why Did Bloom Energy Stock Jump 10% Today?

MarketWatch

Want to help your adult kids and grandkids? Give them money while you’re still alive.

MarketBeat

Energy Vault (NRGV) Set to Post Quarterly Earnings on Tuesday

CNBC

Morgan Stanley's Ariana Salvatore on U.S. midterms: Executive policy is the story for markets

TheStreet

Analyst sends big warning on gold and bitcoin amid U.S. midterms

TipRanks